Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

NCT04671420 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped sponsor strategy decision

Conditions

CD20-positive Follicular Lymphoma, With Low Tumour Burden

Interventions

DRUG: HLX01
DRUG: Mabthera®

Sponsor

Shanghai Henlius Biotech